Case report describes vaginal cuff recurrence in a young woman with cervical carcinosarcoma, suggesting paclitaxel-carboplatin for treatment.
Cervical carcinosarcoma, also known as malignant mixed Müllerian tumor of the cervix, is an extremely rare and aggressive malignancy, accounting for less than 0.005% of cervical cancers. It is associated with rapid progression, high recurrence rates, and limited evidence to guide optimal management. Here, we report a case of cervical carcinosarcoma who developed an early vaginal cuff recurrence after initial surgery. A 43-year-old woman underwent total abdominal hysterectomy for abnormal uterine bleeding at referring hospital. Histopathologic review at our center confirmed cervical carcinosarcoma. In the absence of standardized guidelines, treatment was extrapolated from uterine carcinosarcoma data, where paclitaxel-carboplatin has shown survival benefit and acceptable toxicity. Postoperative imaging identified vaginal cuff mass consistent with recurrence. After three cycles of chemotherapy, radiologic tumor reduction was observed, and completion of six cycles resulted in marked response with resolution of bleeding and no residual symptoms. This case highlights the aggressive nature of cervical carcinosarcoma and supports paclitaxel-carboplatin as potential therapeutic option, emphasizing the need for individualized management and further research.
No takes yet. Share an insight, caveat, or question.
Brahmantara et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: